Thomas S. J. Crabtree
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists
Crabtree, Thomas S. J.; Adamson, Karen; Reid, Hazel; Barnes, Dennis; Sivappriyan, Siva; Bickerton, Alex; Gallen, Ian W.; Field, Benjamin C. T.; Idris, Iskandar; Ryder, Robert E. J.
Authors
Karen Adamson
Hazel Reid
Dennis Barnes
Siva Sivappriyan
Alex Bickerton
Ian W. Gallen
Benjamin C. T. Field
ISKANDAR IDRIS Iskandar.Idris@nottingham.ac.uk
Professor of Diabetes and Metabolic Medicine
Robert E. J. Ryder
Abstract
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.
Citation
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., …Ryder, R. E. J. (2022). Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism, 24(7), 1398-1401. https://doi.org/10.1111/dom.14701
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 22, 2022 |
Online Publication Date | Apr 7, 2022 |
Publication Date | 2022-07 |
Deposit Date | Apr 22, 2022 |
Publicly Available Date | Apr 22, 2022 |
Journal | Diabetes, Obesity and Metabolism |
Print ISSN | 1462-8902 |
Electronic ISSN | 1463-1326 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 24 |
Issue | 7 |
Pages | 1398-1401 |
DOI | https://doi.org/10.1111/dom.14701 |
Keywords | Endocrinology; Endocrinology, Diabetes and Metabolism; Internal Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/7786064 |
Publisher URL | https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14701 |
Files
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists
(349 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search